Racial disparities in drug trials, and disparities in overall medical care, among other factors, make the recently-approved Alzheimer's break-through drug lecanemab less likely to benefit African Americans.
Racial disparities in drug trials, and disparities in overall medical care, among other factors, make the recently-approved Alzheimer's break-through drug lecanemab less likely to benefit African Americans.
1 Comments
108beads@lemm.ee · 2 pts · 3y
Update: same holds true for Latinos.
https://www.beingpatient.com/maria-aranda-clinical-trials-latino-alzheimers/